The Role of Microparticles as a Biomarker

University of Rochester

Status: Withdrawn

Conditions: Atypical Hemolytic Uremic Syndrome; Thrombotic Thrombocytopenic Purpura; Microparticles; Microangiopathic Hemolytic Anemia

Study type: Observational

Funder types: Other

Identifiers

NCT02626663

RSRB00059370

Details and patient eligibility

About

The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with MAHA, TTP, and/or aHUS

Exclusion criteria

• Prisoners

Trial design

0 participants in 3 patient groups

aHUS

Description:

atypical Hemolytic Uremic Syndrome

TTP

Description:

Thrombotic thrombocytopenic purpura

MAHA

Description:

other microangiopathic hemolytic anemias